The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Practical approaches to MRD and genomic testing in myeloma
Benjamin Diamond, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses practical approaches to implementing measurable residual disease (MRD) and genomic testing in routine multiple myeloma care. Dr Diamond highlights the use of archived bone marrow samples for retrospective clonoSEQ clonality identification, alongside flow cytometry and targeted sequencing panels, to support disease monitoring and personalized treatment decisions. This interview took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
